Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection
Infectious Diseases and Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 21, 2025
Recurrent
Clostridioides
difficile
infection
(rCDI)
is
common,
with
symptoms
ranging
from
diarrhea
to
life-threatening
sepsis.
This
study
aimed
assess
the
real-world
outcomes
of
patients
rCDI
in
United
States
(US)
who
received
fecal
microbiota,
live-jslm
(RBL),
first
US
Food
and
Drug
Administration-approved
microbiota-based
therapy
for
prevention
after
antibiotic
treatment.
Adults
RBL
between
July
2023
August
2024
at
home
or
a
clinic
had
≥
8
weeks
follow-up
experienced
CDI
recurrence
any
time
administration
were
included.
Treatment
success,
defined
as
no
within
RBL,
was
assessed
overall
subgroups
stratified
by
age,
number
prior
recurrences,
duration
washout
period,
bezlotoxumab
use,
setting.
Among
196
176
either
<
but
during
that
period.
The
treatment
success
rate
83.0%.
No
significant
differences
observed
rates
among
based
on
age
(<
65
years
old
vs.
old:
85.9%
80.2%,
p
=
0.20),
period
(24
h:
80.0%,
48
84.5%,
72
85.0%,
0.68),
recurrences
3
3:
82.5%
83.1%,
0.60),
use
(86.4%
83.7%,
1.00).
Patients
receiving
higher
compared
those
(87.3%
62.5%,
0.01).
highly
effective
preventing
setting,
including
at-home
administration.
effectiveness
also
high-risk
subgroups,
such
recurrences.
Язык: Английский
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases
Expert Opinion on Biological Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 26, 2025
The
microbiota
composition
in
humans
varies
according
to
the
anatomical
site
and
is
crucial
for
maintaining
homeostasis
an
overall
healthy
state.
Several
gastrointestinal,
vaginal,
respiratory,
skin
diseases
are
associated
with
dysbiosis.
Alternative
therapies
such
as
transplantation
can
help
restore
normal
be
implemented
treat
clinically
relevant
diseases.
Current
conducted
clinical
trials
were
included
this
review
(after
searching
on
MEDLINE
database
from
years
2017
2025)
fecal
(FMT)
against
recurrent
Clostridiodes
difficile
infection
(rCDI)
vaginal
(VMT)
bacterial
vaginosis.
Washed
(WMT)
live
biotherapeutic
products
(LBPs)
also
reviewed.
In
microbiota-based
therapy,
selecting
optimal
donors
a
limitation.
A
stool
or
bank
should
overcome
time-consuming
expensive
process
of
donor
recruitment.
Microbiota-based
LBPs
promising
treatment
alternatives
rCDI
other
dysbiosis-associated
Specific
could
engineered
out
fluids-derived
strains
achieve
selection
specific
beneficial
microorganisms
Personalized
treatments
solutions
diseases,
which
remains
important
necessity
practice.
Язык: Английский
The Microbiota–Human Health Axis
Microorganisms,
Год журнала:
2025,
Номер
13(4), С. 948 - 948
Опубликована: Апрель 20, 2025
Trillions
of
microorganisms
play
a
pivotal
role
in
maintaining
health
and
preventing
disease
humans.
Their
presence
influences
daily
life,
habits,
energy
levels,
pathologies.
The
present
narrative
review
synthesized
recent
studies
microbial
diversity
across
organ
systems.
composition
the
microbiota
regulates
intestinal
barrier,
modulates
immune
response,
metabolism,
produces
essential
compounds
such
as
short-chain
fatty
acids
neurotransmitters.
Dysbiosis
is
associated
with
numerous
pathologies,
including
metabolic,
autoimmune,
neurodegenerative,
cardiovascular
diseases.
key
to
physiological
balance
reducing
risk.
Therapeutic
interventions,
probiotics,
prebiotics,
postbiotics,
microbiome
transplantation,
offer
promising
perspectives
restoring
homeostasis
chronic
Язык: Английский
Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances
European journal of medical research,
Год журнала:
2024,
Номер
29(1)
Опубликована: Окт. 5, 2024
Язык: Английский
Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease
MedComm,
Год журнала:
2024,
Номер
5(12)
Опубликована: Дек. 1, 2024
Abstract
Increasing
evidences
indicate
that
the
gut
microbiota
is
involved
in
development
and
therapy
of
gastrointestinal
hepatic
disease.
Imbalance
occurs
early
stages
diseases,
maintaining
balance
provides
a
new
strategy
for
treatment
diseases.
It
has
been
reported
Parabacteroides
distasonis
associated
with
multiple
As
next‐generation
probiotics,
several
studies
have
demonstrated
its
positive
regulation
on
disease,
including
inflammatory
bowel
colorectal
cancer,
fibrosis,
fatty
liver.
The
function
P.
metabolites
mainly
affect
host
immune
system,
intestinal
barrier
function,
metabolic
networks.
Manipulation
natural
components
lead
to
protective
effect
enterohepatic
In
this
review,
pathways
regulated
by
are
summarized
illustrate
active
their
impact
metabolism,
role
action
mechanism
disease
discussed.
More
importantly,
can
be
used
manipulate
as
strategies,
challenges
perspectives
clinical
applications
Язык: Английский
The case for microbial intervention at weaning
Gut Microbes,
Год журнала:
2024,
Номер
16(1)
Опубликована: Окт. 28, 2024
Weaning,
the
transition
from
a
milk-based
diet
to
solid
food,
coincides
with
most
significant
shift
in
gut
microbiome
composition
lifetime
of
mammals.
Notably,
this
period
also
marks
"window
opportunity"
where
key
components
immune
system
develop,
and
host-microbe
interactions
shape
long-term
homeostasis
thereby
influencing
risk
autoimmune
inflammatory
diseases.
This
review
provides
comprehensive
analysis
changes
nutrition,
microbiota,
host
physiology
that
occur
during
weaning.
We
explore
how
these
weaning-associated
processes
differ
across
species,
lifestyles,
regions
intestine.
Using
prinicples
microbial
ecology,
we
propose
weaning
is
an
optimal
for
microbiome-targeted
therapeutic
interventions.
Additionally,
suggest
replicating
features
adults
could
promote
successful
engraftment
probiotics.
Finally,
highlight
research
areas
deepen
our
understanding
complex
relationships
between
diet,
commensal
microbes,
host,
informing
development
more
effective
therapies.
Язык: Английский
Fecal microbiota transplantation as a possibility of curing Irritable Bowel Syndrome FMT as a possibility of curing IBS
Progress in Health Sciences,
Год журнала:
2024,
Номер
14(1), С. 41 - 49
Опубликована: Июнь 19, 2024
Introduction
and
Objective.
Irritable
Bowel
Syndrome
(IBS)
became
recently
a
common
problem
among
the
population
of
highly
developed
countries.
Most
patients
suffer
from
chronic
abdominal
pain
various
bowel
habit
disorders.
Although
pathogenesis
IBS
was
not
yet
entirely
defined,
intestinal
dysbiosis
is
frequently
mentioned
as
one
most
possible
mechanisms.
There
may
be
way
to
permanently
cure
IBS,
by
replacing
patient’s
dysbiotic
microflora
with
Fecal
Microbiota
Transplantation
(FMT)
healthy
donor.
The
purpose
this
paper
present
FMT
method
treatment.Review
methods.
Search
using
PubMed
database
combined
keywords:
"Irritable
Syndrome",
"Fecal
Transplantation",
"Dysbiosis"
"Intestinal
Microbiota".
An
attempt
made
comprehensive
state
knowledge
while
indicating
areas
that
require
further
research.
Brief
description
knowledge.
Effectiveness
in
has
been
clinically
proven
seems
donor-dependent.
Superdonor’s
microbiota
profile
defined
yet.
gradually
gaining
popularity
new
research
appears
confirming
long-term
effectiveness
procedure.Summary.
Research
results
are
promising
it
likely
will
introduced
treatment
routinely
used
clinical
practice.
Differences
test
related
use
material
donors.
It
important
establish
exact
dosage,
frequency
procedure,
criteria
for
selecting
superdonors,
if
more
than
donor
should
used,
other
things.
Язык: Английский
Clostridioides difficile Infection in the Elderly: Trend Analysis from 2000 to 2019
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(13), С. 3740 - 3740
Опубликована: Июнь 26, 2024
Background/Objective:
Clostridioides
difficile
infection
(CDI)
is
a
common
healthcare-associated
ailment,
presenting
major
health
and
economic
challenges,
especially
for
the
elderly.
Despite
its
prevalence,
comprehensive
data
about
CDI's
impact
on
elderly
are
limited.
Methods:
This
study
used
Global
Burden
of
Disease
Study
2019
to
analyze
CDI
trends
from
2000
2019,
considering
factors
like
sex,
region,
sociodemographic
index
(SDI).
Results:
revealed
that
caused
approximately
18,181
deaths
252,709
disability-adjusted
life
years
(DALYs)
among
worldwide.
The
Americas
showed
highest
burden,
while
Eastern
Mediterranean
saw
steepest
rate
increase
2019.
Regions
with
high
SDI
also
displayed
substantial
impact.
Conclusions:
escalating
burden
in
elderly,
high-SDI
areas
Americas,
emphasizes
an
urgent
need
targeted
public
strategies.
Язык: Английский